Clinical trials: Leucovorin
Cancer of the Rectum
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy (CRT), versus preoperative CRT in patients with…
- Trial name
- Néofirinox (NCT01804790)
- Testing
- mFolfirinox, Radiotherapy 50 Gy, Capecitabine
- Where
- 36 sites in France
- Volunteers
- 461 people
- Sponsor
- UNICANCER
Colorectal Neoplasms, Colonic Neoplasms
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose…
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00056446
- Testing
- Vatalanib
- Where
- 251 sites in United States, Australia and 16 more
- Volunteers
- 855 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer
- Trial name
- NCT00364013
- Testing
- Panitumumab, FOLFOX regimen
- Volunteers
- 1,183 people
- Sponsor
- Amgen
Biliary Tract Cancer
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin for…
- Trial name
- NCT03785873
- Testing
- Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy
FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
The main cause of recurrence after surgical treatment of colorectal cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy.
- Conditions
- High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy, FOLFOXIRI Regimen
- Trial name
- NCT05018182
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- China
- Volunteers
- 69 people
- Sponsor
- West China Hospital
Colorectal Neoplasms
Colorectal Cancer RECHALLENGE
Primary Objective: To demonstrate that re-challenge with an oxaliplatin based regimen (modified FOLFOX-6) will provide a clinical disease control rate (DCR) of at least 20% at the end of the chemotherapy.
- Trial name
- NCT00988897
- Testing
- OXALIPLATIN (SR96669), 5-FLUOROURACIL (5-FU), LEUCOVORIN (LV)
- Where
- Canada
- Sponsor
- Sanofi
Colorectal Cancer
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Although treatment for metastatic colorectal cancer has improved significantly over the recent years, it still remains a significant health problem representing the leading cancer by incidence in the United States of America.
- Trial name
- NCT00199797
- Testing
- Oxaliplatin, 5-Fluorouracil, Leucovorin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- Ludwig Institute for Cancer Research
Neoplasm Metastasis, Colorectal Cancer
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
The FIRE-3 trial is a multicenter randomized phase III trial investigating 5-FU, folinic acid and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment of metastatic colorectal cancer.
- Trial name
- NCT00433927
- Testing
- 5-FU, folinic acid, irinotecan
- Where
- Germany
- Volunteers
- 568 people
- Sponsor
- PD Dr. med. Volker Heinemann
Gastric Cancer
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with 5-fluorouracil, folinic Acid, and oxaliplatin (mFOLFOX6) in participants with…
- Trial name
- NCT01662869
- Testing
- 5-Fluoruracil, Folinic acid, Onartuzumab
- Where
- 125 sites in United States, Australia and 22 more
- Volunteers
- 564 people
- Sponsor
- Hoffmann-La Roche
Resectable Pancreatic Cancer
Borderline Pancreas Study: FOLFIRINOX +SBRT
Primary Objective: To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy. Secondary Objective(s): 1.
- Trial name
- GCC 1324 (NCT01992705)
- Testing
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Maryland, Baltimore
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan (ABBV-400) is…
- Conditions
- Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- AndroMETa-GEA (NCT06628310)
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Fluorouracil
- Where
- 49 sites in United States, Belgium and 9 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Pancreatic Cancer
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
The investigators hypothesize that the combination of the FOLFIRINOX regimen (a combination of 5-fluorouracil, irinotecan and oxaliplatin chemotherapy) to provide maximal systemic disease control and FDR-gemcitabine chemotherapy…
- Trial name
- NCT01661088
- Testing
- FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Liver Metastasis, Colorectal Cancer
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined…
- Trial name
- ATOM ES (NCT01834014)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- EPS Corporation
Colorectal Cancer, Non Resectable Metastasis
Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase
The aim of the study was to evaluate the feasibility of TS determination in a multicenter trial setting using a central facility for measurement and confirm its role as predictive factor for 5-FU treatment in MCRC.
- Conditions
- Colorectal Cancer, Non Resectable Metastasis, Reference Lesion, Biopsy
- Trial name
- FOGT5 (NCT01212718)
- Testing
- FUFA, systemic chemotherapy
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- University of Ulm
Pancreatic Cancer
Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Surgery to remove the pancreas, some of the small intestine, and lymph nodes may be more effective treatment for cancer of the pancreas than surgery to remove the pancreas and some of the small intestine alone.
- Trial name
- NCT00003049
- Testing
- fluorouracil, leucovorin calcium, conventional surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Efficacy, Self, Safety Issues
First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer
This is a prospective, multi-center, randomized controlled clinical intervention study, aiming to explore the effectiveness and safety of mfolfox6 and hlx04 regimens combined with slulimumab as first-line treatment for MSS-type…
- Conditions
- Efficacy, Self, Safety Issues, Colo-rectal Cancer
- Trial name
- NCT06491355
- Testing
- mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sir Run Run Shaw Hospital
Colorectal Cancer Metastatic
Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network
National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only…
- Trial name
- SULTAN (NCT03164655)
- Testing
- Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
- Where
- 4 sites in France
- Volunteers
- 20 people
- Sponsor
- UNICANCER
Rectal Cancer
Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer
The standard treatment for stage 2/3 rectal cancer is neoadjuvant 5-Fu based chemoradiation. However, preoperative radiation cause kinds of adverse events, some were irreversible. And the survival benefit was not obvious.
- Trial name
- FORTUNE (NCT02217020)
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Pancreas Cancer
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
This is an single-center, prospective, open-label clinical trial, to explore the safty and efficacy of combination of Bortezomib, Sindilizumab, and mFOLFIRINOX Chemotherapy (oxaliplatin, fluorouracil, irinotecan, leucovorin) in…
- Trial name
- CISPD-7 (NCT06572813)
- Testing
- Bortezomib Injection, Sintilimab, mFOLFIRINOX
- Where
- China
- Volunteers
- 63 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- ACCELERATE (NCT06574620)
- Testing
- Genetic testing, Optional biopsy, Tissue collection
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- British Columbia Cancer Agency
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.